J0598 Injection, c-1 esterase inhibitor (human), cinryze, 10 units

Billable / valid for submission HCPCS Release 2026Q3

Short description: C-1 esterase, cinryze

Version history

Release	Valid from	Valid to	Description	Billable
2026Q3	2026-07-01	current	Injection, c-1 esterase inhibitor (human), cinryze, 10 units	yes

J0500 Injection, dicyclomine hcl, up to 20 mg
J0515 Injection, benztropine mesylate, per 1 mg
J0517 Injection, benralizumab, 1 mg
J0520 Injection, bethanechol chloride, myotonachol or urecholine, up to 5 mg
J0525 Injection, cefotetan disodium, 10 mg
J0528 Injection, fosfomycin disodium, 20 mg
J0558 Injection, penicillin g benzathine and penicillin g procaine, 100,000 units
J0561 Injection, penicillin g benzathine, 100,000 units
J0565 Injection, bezlotoxumab, 10 mg
J0567 Injection, cerliponase alfa, 1 mg
J0570 Buprenorphine implant, 74.2 mg
J0571 Buprenorphine, oral, 1 mg
J0572 Buprenorphine/naloxone, oral, less than or equal to 3 mg buprenorphine
J0573 Buprenorphine/naloxone, oral, greater than 3 mg, but less than or equal to 6 mg buprenorphine
J0574 Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine
J0575 Buprenorphine/naloxone, oral, greater than 10 mg buprenorphine
J0577 Injection, buprenorphine extended-release (brixadi), less than or equal to 7 days of therapy
J0578 Injection, buprenorphine extended release (brixadi), greater than 7 days and up to 28 days of therapy
J0582 Injection, bivalirudin (endo), not therapeutically equivalent to j0583, 1 mg
J0583 Injection, bivalirudin, 1 mg